catalyst calendar
/
← Catalyst calendar

SXTP biotech catalysts & pipeline

60 DEGREES PHARMACEUTICALS INC · Data as of 2026-10-25

Upcoming catalysts

ARAKODA (tafenoquine) — Initial data

January 2027

The Company plans to unblind the study and report its primary and secondary endpoint results in January 2027, and to submit a request for a pre- supplemental New Drug Application (sNDA) meeting with the U.S. Food and Drug Administration (FDA) that same month.
Source filing

ARAKODA (tafenoquine) — FDA meeting

Jan 2027

A pre-sNDA meeting is planned for late January 2027 after the hospital study unblinds and the expanded-access package is updated.
Source filing

ARAKODA (tafenoquine) — NDA/BLA submission

APR 2027

APR 2027 Final sNDA submission
Source filing

ARAKODA (tafenoquine) — PDUFA

Q4 2027

Q4 2027 Potential PDUFA date with priority review
Source filing

Explore the free biotech catalyst calendar